fashion -WSS

fashion

author：entertainment 2025-09-30 01:12:40 - browse：222

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Biogen shutters digital health group, ends Apple study, in cost cutting move

WSS

Sudafed saga points to U.S. issues with evaluating older drugs

Acelyrin, a rare IPO success, stumbles in its first big test

FDA advisers vote against ALS treatment from BrainStorm

Sudafed saga points to U.S. issues with evaluating older drugs

Popular nasal decongestant doesn't actually relieve congestion

How housing is health care on Long Island

focus

fashion

knowledge

Apple is now the first public company to be valued at $3 trillion

Food makers to regulators: Ultra

BioMarin wins approval for gene therapy to treat hemophilia A

Covid vaccines: Private market messier than government rollout

23andMe had bad news about my health. I wish a person had delivered it

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Apple is now the first public company to be valued at $3 trillion

Telehealth for opioid use disorder is lifesaving

Affirmative action in medical school literally saved lives

White House touts steps to stem shortages of cancer treatments

leisure time

FDA proposes changes to key medical devices approval pathway

Biogen shutters digital health group, ends Apple study, in cost cutting move

New weight loss drugs vying to be the next Wegovy or Mounjaro

How medical schools plan to diversify without affirmative action

How housing is health care on Long Island

Kaiser Permanente unions announce official strike date

hotspot

knowledge

focus

entertainment